LFWD Lifeward Ltd.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1607962 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.1%
TTM net income YoY-9.6%
TTM EPS YoY74.7%
Revenue 3-yr CAGR32.0%
Net income 3-yr CAGR—
Margins
Gross margin31.5%
Operating margin-121.5%
Net margin-155.4%
FCF margin-93.3%
EBITDA margin-120.2%
Returns
ROE-326.8%
ROA-121.9%
ROIC (approx.)-308.2%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets76.2%
Debt / equity0.00x
Current ratio2.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-48.8%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.43M | $6.62M | $3.92M | $5.08M | $6.20M | $5.72M | $5.03M | $7.54M |
| Cost of revenue | $3.94M | $3.91M | $2.58M | $3.99M | $3.49M | $3.21M | $2.91M | $5.70M |
| Gross profit | $1.49M | $2.71M | $1.34M | $1.09M | $2.71M | $2.51M | $2.12M | $1.84M |
| R&D expense | $1.94M | $1.75M | $5.84M | $843,000 | $721,000 | $767,000 | $918,000 | $1.13M |
| SG&A expense | $2.17M | $1.58M | $2.56M | $2.28M | $1.96M | $1.74M | $2.22M | $1.77M |
| Operating income | -$5.97M | -$4.15M | -$10.34M | -$5.12M | -$3.14M | -$6.56M | -$4.85M | -$15.23M |
| Interest expense | $405,000 | $7.07M | $416,000 | — | — | — | — | — |
| Pretax income | -$5.04M | -$11.51M | -$10.79M | -$5.42M | -$3.16M | -$6.56M | -$4.82M | -$15.28M |
| Income tax | $8,000 | $10,000 | $6,000 | -$73,000 | $7,000 | $0 | $11,000 | $3,000 |
| Net income | -$5.05M | -$11.52M | -$10.79M | -$5.35M | -$3.17M | -$6.56M | -$4.83M | -$15.28M |
| EBITDA | -$5.89M | -$4.08M | -$10.28M | -$5.05M | -$3.06M | -$6.47M | -$4.76M | -$15.10M |
| EPS (basic) | -1.32 | -4.12 | -6.70 | — | -2.37 | -7.01 | -5.53 | — |
| EPS (diluted) | -1.32 | -4.12 | -6.70 | — | -2.37 | -7.01 | -5.53 | — |
| Weighted avg. shares (diluted) | 3.84M | 2.80M | 1.61M | — | 1.34M | 935,785 | 873,845 | — |
| Banking | ||||||||
| Net interest income | — | — | — | -$312,000 | $0 | $0 | $0 | -$2,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $4.55M | $9.45M | $11.42M | $2.17M | $2.36M | $5.52M | $6.09M | $7.11M |
| Receivables | $7.65M | $7.86M | $5.66M | $6.14M | $6.13M | $5.86M | $5.17M | $6.00M |
| Inventory | $6.70M | $6.15M | $6.25M | $5.73M | $7.11M | $7.62M | $6.80M | $6.72M |
| Current assets | $21.70M | $25.95M | $25.56M | $15.81M | $17.35M | $20.71M | $19.82M | $21.29M |
| PP&E, net | $463,000 | $527,000 | $571,000 | $585,000 | $641,000 | $730,000 | $777,000 | $867,000 |
| Goodwill | $4.75M | $4.75M | $4.75M | $4.75M | $4.75M | $4.75M | $7.54M | $7.54M |
| Intangibles | — | — | — | — | — | — | $0 | $0 |
| Total assets | $30.52M | $35.00M | $33.42M | $22.90M | $23.17M | $26.78M | $28.81M | $30.49M |
| Current liabilities | $10.86M | $11.16M | $10.63M | $12.04M | $9.05M | $10.36M | $9.07M | $10.22M |
| Total liabilities | $23.25M | $22.78M | $27.13M | $14.49M | $10.41M | $11.67M | $10.35M | $11.64M |
| Shareholders' equity | $7.27M | $12.22M | $6.29M | $8.41M | $12.76M | $15.11M | $18.46M | $18.85M |
| Shares outstanding | 2.84M | 2.83M | 2.78M | 1.52M | 16.86M | 15.66M | 10.63M | 733,966 |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.38M | -$6.00M | -$3.67M | -$3.56M | -$3.84M | -$3.94M | -$5.49M | -$3.97M |
| Capital expenditure | $0 | $8,000 | $0 | $11,000 | $0 | $0 | $5,000 | $0 |
| Free cash flow | -$6.38M | -$6.01M | -$3.67M | -$3.57M | -$3.84M | -$3.94M | -$5.50M | -$3.97M |
| Investing cash flow | -$6.50M | -$28,000 | $6.50M | -$11,000 | $0 | $0 | -$5,000 | $0 |
| Financing cash flow | $8.00M | $4.08M | $6.42M | $3.78M | $646,000 | $3.31M | $4.47M | $0 |
| Depreciation & amortization | $75,000 | $68,000 | $59,000 | $72,000 | $83,000 | $88,000 | $90,000 | $124,000 |
| Stock-based compensation | $103,000 | $262,000 | $177,000 | $167,000 | $174,000 | $182,000 | $220,000 | $234,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.